[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346121-105":59,"doc-detail-346121-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","sodium-glucose-cotransporter-2-inhibitors-and-gastrointestinal-neoplasm-risk-in-type-2-diabetes-a-systematic-review-and-metaanalysis-of-randomized-controlled-trials","Sodium-glucose cotransporter 2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes - a systematic review and metaanalysis of randomized controlled trials","","The potential carcinogenic effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus remain controversial, especially for site-specific gastrointestinal neoplasms. This systematic review and meta-analysis searched major databases through March 17, 2025 for randomized controlled trials comparing SGLT2 inhibitors with placebo or active comparators. Two reviewers screened studies, extracted data, assessed bias, and pooled odds ratios using Stata 17.0. Across 48 RCTs (n=48,765), SGLT2 therapy showed no association with overall GI neoplasm risk, and site-specific and subgroup analyses were non-significant. Short follow-up and non-cancer-specific outcome ascertainment limit conclusions, yielding reassuring but not definitive long-term oncologic safety evidence.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sodium-glucose-cotransporter-2-inhibitors-and-gastrointestinal-neoplasm-risk-in-type-2-diabetes-a-systematic-review-and-metaanalysis-of-randomized-controlled-trials/346121/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sodium-glucose-cotransporter-2-inhibitors-and-gastrointestinal-neoplasm-risk-in-type-2-diabetes-a-systematic-review-and-metaanalysis-of-randomized-controlled-trials/346121.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main objective of this systematic review and meta-analysis?","Question",{"text":113,"@type":114},"To determine the relationship between SGLT2 inhibitors and the risk of gastrointestinal neoplasms in patients with type 2 diabetes mellitus using randomized controlled trial evidence.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Do SGLT2 inhibitors increase overall gastrointestinal neoplasm risk in the analyzed RCTs?",{"text":118,"@type":114},"No. Pooled results across 48 RCTs showed no statistically significant association with overall GI neoplasm risk (OR 1.10, 95% CI 0.84–1.44; p=0.46).",{"name":120,"@type":111,"acceptedAnswer":121},"Why should the findings be interpreted cautiously regarding long-term oncologic safety?",{"text":122,"@type":114},"Approximately half of the trials had follow-up of one year or less, limiting assessment of long-term risk; additionally, outcome ascertainment often reflected adverse events rather than centrally adjudicated cancer endpoints.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346121,1790189435,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Clinical and Experimental Medicine (2026) 26:319  \n[https://doi.org/10.1007/s10238-026-02300-6](https://doi.org/10.1007/s10238-026-02300-6)  \nREVIEW  \nSodium-glucose cotransporter-2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes: a systematic review and metaanalysis of randomized controlled trials  \nYu-Fan Zhang1,2 · Jia-Jie Xie1,2 · Qi Wu2,3,5 · Xiao-Yu Zhou2 · Chen Zeng1,2 · Yan Zeng1,2 · Yi-Meng He1,2 · Man Guo1,2,3,4 · Fang-Yuan Teng1,2,3,4 · Yong Xu1,2,3,4  \nReceived: 31 March 2026 / Accepted: 17 August 2026 © The Author(s) 2026  \nAbstract  \nThe potential carcinogenic effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) remain controversial, particularly regarding site-specific gastrointestinal (GI) neoplasms. This systematic review and meta-analysis aimed to determine the relationship between SGLT2 inhibitors and the risk of GI neoplasms inpatients with T2DM. We searched PubMed, EMBASE, Cochrane CENTRAL, Scopus, and Web of Science through March 17, 2025, for RCTs in T2DM comparing SGLT2 inhibitors with placebo or active comparators. Two reviewers independently screened studies, extracted data, and assessed the risk of bias. The primary outcome was GI neoplasms reported in publications, supplementary materials, or trial registries, usually as adverse events rather than centrally adjudicated cancer endpoints. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated in Stata 17.0. In 48 RCTs (n = 48,765), SGLT2 inhibitor therapy was not associated with overall GI neoplasm risk (OR = 1.10, 95% CI: 0.84–1.44; p = 0.46; I² = 0%) . Site-specific analyses showed no statistically significant association for esophageal (OR = 1.12, 95% CI 0.37–3.45), gastric (1.20, 0.65–2.23), hepatic (0.62, 0.31–1.22), pancreatic (0.91, 0.51–1.64), colonic (1.28, 0.78–2.08), colorectal (0.76, 0.27–2.17), and rectal neoplasms (0.98, 0.49–1.97), with allp-values >0.05. Subgroup analyses by agents (e.g., canagliflozin, dapagliflozin, empagliflozin), baseline age, body mass index (BMI), HbA1c, treatment duration, and dose were also non-significant (all p>0.05) . Approximately half of the trials had follow-up of one year or less, limiting our ability to evaluate long-term risk. Available RCT evidence does not show a clear increase in GI neoplasm risk with SGLT2 inhibitors in T2DM. However, limited follow-up, low event counts, and non-cancer-specific outcome ascertainment, the findings should be interpreted as reassuring but not definitive evidence of long-term oncologic safety.  \nSystematic review registration: PROSPERO No. CRD42024619019 .  \nKeywords SGLT2 inhibitors · Type 2 diabetes · Gastrointestinal neoplasms · Meta-analysis · Canagliflozin · Empagliflozin · Dapagliflozin  \nYu-Fan Zhang, Jia-Jie Xie and Qi Wu contributed equally to this work.  \n Man Guo [guoman613@swmu.edu.cn](guoman613@swmu.edu.cn)  \n Fang-Yuan Teng [tengfangyuan383@swmu.edu.cn](tengfangyuan383@swmu.edu.cn)  \n Yong Xu [xywyll@swmu.edu.cn](xywyll@swmu.edu.cn)  \n1 Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, China  \n2 School of Clinical Medicine, Southwest Medical University, Luzhou 646000, Sichuan, China  \n3 Metabolic Vascular Diseases Key Laboratory of Sichuan Province, and Metabolic Vascular Diseases Key Laboratory of Sichuan-Chongqing Cooperation, Luzhou 646000, Sichuan, China  \n4 Sichuan Clinical Research Center for Nephropathy, and Sichuan Clinical Research Center for Diabetes and Metabolic Disease, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, China  \n5 Department of Pathology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, China  \nAbbreviations  \nSGLT2  \nGLP-1  \nDPP-4  \nGI  \nORs  \nCis  \nHR  \nI²  \nSD  \nRoB 2  \nRCTs  \nT2DM  \nBMI  \nHbA1c  \nCENTRAL  \nSodium-glucose cotransporter 2  \nGlucagon-like peptide-1  \nDipeptidyl peptidase-4  \nGastr","cbCaifEUiUDp94El","https://ap.wps.com/l/cbCaifEUiUDp94El","pdf",2965052,21,"English","# Abstract\n# Introduction\n## Global burden of diabetes and cancer risk\n## Rationale for SGLT2 inhibitors\n## Evidence from observational studies\n## Evidence from randomized controlled trials","[{\"question\":\"What is the main objective of this systematic review and meta-analysis?\",\"answer\":\"To determine the relationship between SGLT2 inhibitors and the risk of gastrointestinal neoplasms in patients with type 2 diabetes mellitus using randomized controlled trial evidence.\"},{\"question\":\"Do SGLT2 inhibitors increase overall gastrointestinal neoplasm risk in the analyzed RCTs?\",\"answer\":\"No. Pooled results across 48 RCTs showed no statistically significant association with overall GI neoplasm risk (OR 1.10, 95% CI 0.84–1.44; p=0.46).\"},{\"question\":\"Why should the findings be interpreted cautiously regarding long-term oncologic safety?\",\"answer\":\"Approximately half of the trials had follow-up of one year or less, limiting assessment of long-term risk; additionally, outcome ascertainment often reflected adverse events rather than centrally adjudicated cancer endpoints.\"}]","Sodium-glucose cotransporter 2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes - a systematic review and metaanalysis of randomized controlled trials | PDF",1790060127,53,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0cfaebb0e7e46fb813f8a5ec686b9af3.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32e2310cac1f6726caca8c15a798e4b1.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1b83b1c9770ad10e8744205d79777d5.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1d28fbc486ac12ad4c64796ee686ad2.webp",980,1301]